RZRuiqing Zhao

Ruiqing Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruiqing Zhao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Jianguo Xu

    National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing 102206, PR China

    4 shared publications
  • Liyun Liu

    National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

    4 shared publications
  • Ruiting Lan

    School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia

    4 shared publications
  • Ruoshi Wang

    National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

    4 shared publications
  • Shuwei Zhang

    National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

    4 shared publications
  • Huijing Tang

    National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

    3 shared publications

Latest Publications

  • Open Access

    Paraclostridium tenue Exhibits Antitumor Activity Through Generating Antitumor Metabolites and Modulating Gut Microbiota

    by Qianhua Fan, Yao Lu, Huijing Tang, Xiaoying Lin, Ruiting Lan, Shuwei Zhang, Ruoshi Wang, Ruiqing Zhao, Hui Sun, Liyun Liu, et al.

    Colorectal cancer (CRC) is a digestive tract malignant tumor with a relatively high incidence and mortality rate worldwide. The occurrence and development of CRC are closely associated with disturbances in the gut microbiota. Paraclostridium tenue (synonym Eubacterium tenue) is generally considered a harmless commensal and can be isolated from fecal samples of healthy adults. However, whether this bacterium is a beneficial organism with an antitumor effect is unknown. This study systematically evaluated the anti-CRC effects of P. tenue strain Pt517 on CRC cells in vitro and in the CT26 syngeneic mouse model. Pt517 culture supernatant (Pt517CS) inhibited the proliferation, colony formation, and migration ability of CRC cells; induced cell apoptosis; and altered cell cycle distribution. Daily intragastric administration of Pt517 significantly inhibited tumor growth in mice; increased the expression levels of TNF-α, INF-γ, and CD8 in tumor tissues; and decreased the levels of IL-6, IL-10, and TGF-β. Pt517 intervention significantly modulated the gut microbiota composition with increased relative abundance of Parabacteroides goldsteinii, Lachnospiraceae, and Enterorhabdus caecimuris B7. The long-chain fatty acids (LCFAs), stearic acid and palmitic acid, were increased in the serum of treatment group mice and detected in Pt517CS. Functional verification indicated that stearic acid and palmitic acid directly inhibited the proliferation of CT26 cells in a dose-dependent manner, suggesting that Pt517 might exert its anti-CRC effect by secreting LCFAs. These findings indicate that P. tenue Pt517 is a potential new candidate for the microbial treatment of CRC, which warrants further validation for its safety and efficacy before clinical translation.

  • Open Access

    Genomic and Metabolomic Insights Into the Probiotic Potential of Weissella viridescens

    by Shuwei Zhang, Ruiting Lan, Ruiqing Zhao, Ruoshi Wang, Liyun Liu, Jianguo Xu

    Weissella viridescens has been proposed as a probiotic candidate, but strain-level multi-omics evidence remains limited. The complete genome of the human-derived W. viridescens strain Wv2365 was sequenced through a hybrid assembly of Illumina and PacBio sequencing reads and compared with eight publicly available W. viridescens genomes. Pangenome analysis and functional annotation were performed, and metabolites were profiled by broadly targeted metabolomic analysis. In addition, the acid and bile tolerance, auto-aggregation and cell surface hydrophobicity, and antioxidant activity of the strain, as well as both in silico and phenotypic safety, were assessed. Wv2365 carries a single chromosome of 1.57 Mb with 41.3% G+C content. The species has an open pangenome with 803 core genes. Genomic and metabolomic features converged on carbohydrate and amino acid metabolism, including glycolysis/tricarboxylic acid (TCA) cycle and arginine pathways, and a carbohydrate-active enzyme (CAZyme) repertoire dominated by glycosyltransferases. In vitro, Wv2365 tolerated pH 3.0 and 0.3% bile, showed auto-aggregation, surface hydrophobicity, and 2,2-diphenyl-1-picrylhydrazyl (DPPH) and hydroxyl radical scavenging. The strain was susceptible to 10 antibiotics tested except for its intrinsic vancomycin non-susceptibility and was non-hemolytic and gelatinase negative. No acquired antimicrobial resistance or virulence genes were found in the genome. These findings indicate that W. viridescens Wv2365 is safe with probiotic traits relevant to gastrointestinal survival, colonization, and redox balance.


  • Open Access

    Alistipes putredinis Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease in Rats via Gut Microbiota Remodeling and Inflammatory Suppression

    by Shuwei Zhang, Ruoshi Wang, Ruiqing Zhao, Yao Lu, Mingchao Xu, Xiaoying Lin, Ruiting Lan, Suping Zhang, Huijing Tang, Qianhua Fan, et al.

    Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver condition linked to obesity and metabolic imbalance. Alterations in the gut microbiota are increasingly recognized as contributors to its progression. Alistipes putredinis, a core member of the human gut microbiota, has been linked with metabolic health, but its functional role in MASLD remains unclear. Methods: This study evaluated the potential of A. putredinis strain Ap77, isolated from the stool of a healthy adult, to mitigate MASLD-related alterations in a high-fat diet (HFD)-induced rat model. Animals were divided into normal chow (NC), HFD, and HFD plus Ap77 groups and received daily oral gavage of Ap77 or PBS for 8 weeks. Results: Ap77 supplementation attenuated the body weight increase associated with high-fat diet consumption. It also reduced hepatic triglyceride levels and fat mass and improved liver histology. Transcriptomic analysis revealed suppression of inflammation-associated pathways. Correspondingly, the concentrations of IL-1β, IL-6, and TNF-α in both the liver and serum were reduced. Ap77 supplementation was associated with an increased abundance of health-associated bacterial genera, such as Lachnospiraceae UCG_010, Akkermansia, and Flavonifractor, as well as elevated serum levels of butyrate, indole-3-propionic acid, and indoleacrylic acid. Notably, correlation analysis revealed that Lachnospiraceae UCG_010 was positively associated with these metabolites. Conclusions: A. putredinis Ap77 alleviates hepatic steatosis and inflammation in MASLD, potentially by reshaping gut microbiota and suppressing inflammation-related signaling pathways.


  • Open Access

    Weissella viridescens Attenuates Hepatic Injury, Oxidative Stress, and Inflammation in a Rat Model of High-Fat Diet-Induced MASLD

    by Shuwei Zhang, Ruiqing Zhao, Ruoshi Wang, Yao Lu, Mingchao Xu, Xiaoying Lin, Ruiting Lan, Suping Zhang, Huijing Tang, Qianhua Fan, et al.

    Background: Metabolic-dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder globally. Probiotic supplementation has shown promise in its prevention and treatment. Although Weissella viridescens, a lactic acid bacterium with immunomodulatory effects, has antibacterial and anti-inflammatory activities, there is a lack of direct evidence for its role in alleviating MASLD. This study aimed to investigate the protective effects of W. viridescens strain Wv2365, isolated from healthy human feces, in a high-fat diet (HFD)-induced rat model of MASLD. Methods: Rats were randomly assigned to a normal chow diet (NC), high-fat diet (HFD), and HFD supplemented with W. viridescens Wv2365 (Wv2365) groups. All groups were fed their respective diets for 8 weeks. During this period, the NC and HFD groups received a daily oral gavage of PBS, while the Wv2365 group received a daily oral gavage of Wv2365. Results: Wv2365 supplementation significantly reduced HFD-induced body weight gain, improved NAFLD activity scores, alleviated hepatic injury, and restored lipid metabolism. A liver transcriptomic analysis revealed the downregulation of inflammation-related pathways, along with decreased serum levels of TNF-α, IL-1β, IL-6, MCP-1, and LPS. Wv2365 also activated the Nrf2/HO-1 antioxidant pathway, enhanced hepatic antioxidant enzyme activities and reduced malondialdehyde levels. A gut microbiota analysis showed the enrichment of beneficial genera, including Butyricicoccus, Akkermansia, and Blautia. Serum metabolomic profiling revealed increased levels of metabolites including indole-3-propionic acid, indoleacrylic acid, and glycolithocholic acid. Conclusions: Wv2365 attenuates hepatic injury, oxidative stress, and inflammation in a rat model of high-fat-diet-induced MASLD, supporting its potential as a probiotic candidate for the modulation of MASLD.


  • Open Access

    AB0202 GUT MICROBIOTA DYSBIOSIS WERE CLOSELY CORRELATED WITH LYMPHOCYTE SUBSETS AND CYTOKINES IN PATIENTS WITH INFLAMMATORY ARTHRITIS

    by J. Liu, S. X. Zhang, J. Qiao, R. Zhao, S. Song, T. Cheng, J. Wang, X. Li, C. Wang

    Background Inflammatory arthritis includes a group of chronic conditions, particularly rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1].Growing evidences link gut microbiota dysbiosis with the development of inflammatory arthritis[2]. Objectives The aim of this study was to discover the characters of microbiota in inflammatory arthritis patients and compare the relationship between the microbiota and peripheral lymphocyte subsets and cytokines. Methods Fecal samples were collected from 73 arthritis patients (13 PsA, 30 AS, 30 RA patients) and 140 sex- and age-matched healthy controls (HCs). The gut microbiota was studied by sequencing the V3-V4 variable regions of bacterial 16S rRNA genes by the Illumina Miseq PE300 system. Peripheral lymphocyte subsets in these participants were assessed by flow cytometry. Measures of disease activity such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) were recorded. Alpha and Beta diversity was assessed using results from QIIME2 and gut microbiome profiles were compared using linear discriminant analysis (LDA) effect size (LEfSe). R (version 4.0.1) was used for comparative statistics, using pearson correlation analysis to assess the correlation between the relative abundance of genus in the sample and clinical parameters. Results Compared with HCs, the richness of gut microbiota (ACE and Chao 1) was significantly lower (p < 0.05) in arthritis patients, and bacterial diversity including Shannon and Simpson indices (p < 0.001) was also significant in arthritis decreased (Figure 1A). β-diversity analysis based on Bray-curtis distance revealed significant differences in microbial communities between arthritis and HCs (Figure 1B, r=0.098, p=0.001, ANOSIM). In addition, compared with HCs at the genus level, 9 bacterial groups were significantly different in PsA (p < 0.05), 19 bacterial groups in AS (p < 0.05), and 17 bacterial groups in RA(p < 0.05) (Figure 1C). There was a significant positive correlation between CD4+T and Prevotella(pConclusion The gut microbiota of patients with inflammatory arthritis differs from HC and also varies among individual arthritis, which was closely related to lymphocyte subsets. References [1]Wu X. Innate Lymphocytes in Inflammatory Arthritis[J]. Front Immunol, 2020, 11: 565275.DOI: 10.3389/fimmu.2020.565275 [2]Breban M. Gut microbiota and inflammatory joint diseases[J]. Joint Bone Spine, 2016, 83(6): 645-649.DOI: 10.1016/j.jbspin.2016.04.005 Acknowledgements This work was supported by the National Natural Science Foundation of China (No. 82001740). Disclosure of Interests None declared